Petra Lutterbuese PhD

Dr. Petra Lutterbuse is a project toxicologist in the department of Translational Safety & Risk Sciences at Amgen and is based in Munich, Germany.  For more than two decades, she has worked on Amgen’s Bispecific T cell Engager (BiTE®) technology and its application in the field of cancer immunotherapy. Petra received her PhD in Immunology from the University of Freiburg, Germany, and the Max Planck Institute of Immunology, Freiburg, in 2003, before joining Micromet, a Munich-based biotechnology company. At the start of her career, she supervised a lab responsible for the increasingly sophisticated in vitro and in vivo pharmacologic characterization of BiTE molecules, supporting efforts to evaluate their efficacy and bring them to the clinic.

Lutterbuse then switched gears,  turned towards toxicology, and is now a Diplomate of the American Board of Toxicology. With the acquisition of Micromet for its BiTE® platform in 2012, Petra joined Amgen, where she now oversees the nonclinical safety assessment of BiTE programs in Amgen’s pipeline across various stages of research and development. She has most recently led the nonclinical safety contribution to the Investigational New Drug application for AMG 305, Amgen’s first dual targeting T cell engage, and is also responsible for pipeline follow-up dual targeting TCEs.